DE3889853D1 - Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik. - Google Patents
Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.Info
- Publication number
- DE3889853D1 DE3889853D1 DE3889853T DE3889853T DE3889853D1 DE 3889853 D1 DE3889853 D1 DE 3889853D1 DE 3889853 T DE3889853 T DE 3889853T DE 3889853 T DE3889853 T DE 3889853T DE 3889853 D1 DE3889853 D1 DE 3889853D1
- Authority
- DE
- Germany
- Prior art keywords
- immunogenic potential
- polysaccharide
- immunoglobulin
- improved pharmacokinetics
- modified immunoglobulins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 3
- 102000018358 immunoglobulin Human genes 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 2
- 229940072221 immunoglobulins Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 229920002307 Dextran Polymers 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 230000004807 localization Effects 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11815087A | 1987-11-05 | 1987-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3889853D1 true DE3889853D1 (de) | 1994-07-07 |
Family
ID=22376776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3889853T Expired - Lifetime DE3889853D1 (de) | 1987-11-05 | 1988-11-03 | Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik. |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0315456B1 (de) |
| JP (1) | JPH01163133A (de) |
| AT (1) | ATE106249T1 (de) |
| AU (1) | AU610946B2 (de) |
| DE (1) | DE3889853D1 (de) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5541297A (en) * | 1988-04-01 | 1996-07-30 | Immunomedics, Inc. | Therapeutic conjugates of toxins and drugs |
| US8038994B2 (en) | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
| US5929049A (en) | 1997-08-08 | 1999-07-27 | Dade Behring Marburg Gmbh | Polysaccharide conjugates of biomolecules |
| HK1042114B (zh) | 1998-10-23 | 2006-09-29 | Amgen K-A, Inc. | 与mp1受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽 |
| US6245879B1 (en) * | 1999-01-29 | 2001-06-12 | Shell Oil Company | Purification of 1,3-propanediol in carbonyl-containing stream |
| US7871597B2 (en) | 1999-04-09 | 2011-01-18 | Amag Pharmaceuticals, Inc. | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| ITMI20010347A1 (it) * | 2001-02-21 | 2002-08-21 | Grisotech S A | Complessi di immunoglobuline e polisaccaridi per assorbimento orale etrans-mucosale |
| EA010435B1 (ru) | 2001-05-11 | 2008-08-29 | Амген, Инк. | Связывающиеся с tall-1 молекулы и их применение |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| CA2496795C (en) | 2002-08-28 | 2014-06-03 | Paul B. Burton | Compositions and methods for treating cardiovascular disease |
| AU2004261941B2 (en) | 2003-07-25 | 2008-04-10 | Amgen Inc. | Antagonists and agonists of LDCAM and methods of use |
| DK1704166T3 (en) | 2004-01-07 | 2015-06-01 | Novartis Vaccines & Diagnostic | M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF |
| JP2008505928A (ja) | 2004-07-08 | 2008-02-28 | アムジェン インコーポレーテッド | 治療用ペプチド |
| EP1797127B1 (de) | 2004-09-24 | 2017-06-14 | Amgen Inc. | Modifizierte fc-moleküle |
| US7906625B2 (en) | 2005-01-24 | 2011-03-15 | Amgen Inc. | Humanized anti-amyloid antibody |
| US8652469B2 (en) | 2005-07-28 | 2014-02-18 | Novartis Ag | M-CSF-specific monoclonal antibody and uses thereof |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| CA2626082C (en) | 2005-10-13 | 2017-04-11 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| AR056806A1 (es) | 2005-11-14 | 2007-10-24 | Amgen Inc | Moleculas quimericas de anticuerpo rankl- pth/ pthrp |
| EP2010569A4 (de) | 2006-03-20 | 2009-09-09 | Xoma Technology Ltd | Für gastrin spezifische humane antikörper, materialien und methoden |
| JO3324B1 (ar) | 2006-04-21 | 2019-03-13 | Amgen Inc | مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| JP5406710B2 (ja) | 2006-05-19 | 2014-02-05 | グライコフィ， インコーポレイテッド | エリスロポエチン組成物 |
| US7981425B2 (en) | 2006-06-19 | 2011-07-19 | Amgen Inc. | Thrombopoietic compounds |
| WO2008002591A2 (en) | 2006-06-26 | 2008-01-03 | Amgen Inc | Methods for treating atherosclerosis |
| MX2009001341A (es) | 2006-08-04 | 2009-05-28 | Novartis Ag | Anticuerpos especificos de ephb3 y usos de los mismos. |
| PL2059535T3 (pl) | 2006-08-18 | 2014-04-30 | Novartis Ag | Przeciwciało specyficzne względem PRLR i jego zastosowanie |
| TW200833840A (en) | 2006-10-25 | 2008-08-16 | Amgen Inc | Toxin peptide therapeutic agents |
| EA200900767A1 (ru) | 2006-12-07 | 2009-12-30 | Новартис Аг | Антагонистические антитела против ephb3 |
| AU2008262490B2 (en) | 2007-05-22 | 2011-11-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| HRP20140315T1 (hr) | 2007-07-26 | 2014-05-09 | Amgen Inc. | Modificirani enzimi lecitin-kolesterol aciltransferaze |
| US8414893B2 (en) | 2007-12-21 | 2013-04-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
| AU2009206306B2 (en) | 2008-01-25 | 2013-06-06 | Amgen Inc. | Ferroportin antibodies and methods of use |
| US9315577B2 (en) | 2008-05-01 | 2016-04-19 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| CA2729012A1 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| KR101651703B1 (ko) | 2008-10-10 | 2016-08-26 | 암젠 인크 | Ｆｇｆ21 돌연변이체 및 이의 용도 |
| WO2010045321A2 (en) | 2008-10-15 | 2010-04-22 | Baxter International Inc. | Pegylation of recombinant blood coagulation factors in the presence of bound antibodies |
| EP3385279B1 (de) | 2009-03-20 | 2020-02-26 | Amgen Inc. | Träger-immunglobuline und verwendungen davon |
| SG10201707763PA (en) | 2009-05-05 | 2017-11-29 | Amgen Inc | FGF21 Mutants And Uses Thereof |
| JP2012525847A (ja) | 2009-05-05 | 2012-10-25 | アムジエン・インコーポレーテツド | Ｆｇｆ２１変異体およびその使用 |
| US8324160B2 (en) | 2009-06-17 | 2012-12-04 | Amgen Inc. | Chimeric polypeptides and uses thereof |
| WO2010148413A2 (en) | 2009-06-19 | 2010-12-23 | Medimmune, Llc | Protease variants |
| US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
| CA2772945A1 (en) | 2009-09-25 | 2011-03-31 | Xoma Technology Ltd. | Screening methods |
| AR079114A1 (es) | 2009-11-20 | 2011-12-28 | Amgen Inc | Proteinas de enlace de antigenos anti-orai1 y usos de las mismas |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| WO2011130417A2 (en) | 2010-04-15 | 2011-10-20 | Amgen Inc. | HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS |
| EP2619226B1 (de) | 2010-09-22 | 2018-09-12 | Amgen Inc. | Träger-immunglobuline und verwendungen davon |
| US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
| LT2714735T (lt) | 2011-06-03 | 2021-12-10 | Xoma Technology Ltd. | Tgf beta specifiniai antikūnai |
| EP2750695A2 (de) | 2011-08-31 | 2014-07-09 | Amgen Inc. | Verfahren zur behandlung oder linderung von typ-1-diabetes mittels fgf21 |
| US9458214B2 (en) | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
| US9006400B2 (en) | 2011-09-26 | 2015-04-14 | Novartis Ag | Fibroblast growth factor-21-Fc fusion proteins |
| NZ631098A (en) | 2013-03-15 | 2016-09-30 | Intrinsic Lifesciences Llc | Anti-hepcidin antibodies and uses thereof |
| US20160235810A1 (en) | 2013-10-18 | 2016-08-18 | Novartis Ag | Methods of treating diabetes and related disorders |
| US10323088B2 (en) | 2014-09-22 | 2019-06-18 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| US20180280474A1 (en) | 2015-10-01 | 2018-10-04 | Amgen Inc. | Treatment of bile acid disorders |
| SI3464318T1 (sl) | 2016-06-02 | 2021-07-30 | Abbvie Inc. | Agonist glukokortikoidnega receptorja in njegovi imunokonjugati |
| PE20201286A1 (es) | 2017-12-01 | 2020-11-24 | Abbvie Inc | Agonista del receptor de glucocorticoides e inmunoconjugados de este |
| CN114096559A (zh) | 2019-03-27 | 2022-02-25 | 蒂嘉特克斯公司 | 工程化iga抗体及其使用方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1541436A (en) * | 1976-02-02 | 1979-02-28 | Searle & Co | Immunological materials |
| NZ214503A (en) * | 1984-12-20 | 1990-02-26 | Merck & Co Inc | Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates |
| US4732863A (en) * | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
| US4699784A (en) * | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
-
1988
- 1988-11-03 EP EP88310372A patent/EP0315456B1/de not_active Expired - Lifetime
- 1988-11-03 DE DE3889853T patent/DE3889853D1/de not_active Expired - Lifetime
- 1988-11-03 AT AT88310372T patent/ATE106249T1/de not_active IP Right Cessation
- 1988-11-04 AU AU24755/88A patent/AU610946B2/en not_active Ceased
- 1988-11-05 JP JP63281158A patent/JPH01163133A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0315456A2 (de) | 1989-05-10 |
| JPH01163133A (ja) | 1989-06-27 |
| AU610946B2 (en) | 1991-05-30 |
| EP0315456A3 (en) | 1990-03-28 |
| AU2475588A (en) | 1989-05-18 |
| EP0315456B1 (de) | 1994-06-01 |
| ATE106249T1 (de) | 1994-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3889853D1 (de) | Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik. | |
| EP0527821A4 (en) | Oxidation resistant thrombomodulin analogs | |
| DK0466409T3 (da) | Polymerblanding | |
| FI903464A0 (fi) | Foerfarande foer oxiderande denaturering av proteinanalyter. | |
| DE59008404D1 (de) | Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oder IgA-haltige Immunglobulinpräparate. | |
| ATE259878T1 (de) | Verfahren zur verbesserung der immunogenität einer immunogenen zusammensetzung oder eines haptens und verwendung zur herstellung von impfstoffen | |
| DE68923895D1 (de) | Herstellung von Polyester mit ultrahohem Molekulargewicht. | |
| DE68906011D1 (de) | Chitosan enthaltendes kosmetisches praeparat. | |
| FR2522967B1 (fr) | Conjugues d'haptenes et de muramyl-peptides, doues d'activite immunogene et compositions les contenant | |
| ATE16603T1 (de) | Immunoglobulinkonjugate. | |
| SE7608174L (sv) | Forfarande for framstellning av antiserum | |
| FI102462B1 (fi) | Menetelmä nimesulidin syklodekstriinikompleksin valmistamiseksi | |
| FI854511A0 (fi) | Vattenloesliga polymerer. | |
| ATE168115T1 (de) | In lösung bringen von proteinen in aktiver form | |
| DK0529019T3 (da) | Nematodevaccine | |
| SE8602523L (sv) | 2-alkyl- eller -aralkyltio-1-cykloalken-1-karboxamider och deras sulfoxider, sett for deras framstellning och deras anvendning for syntes av tri- och 4,5-tetrametylen-4-isotiazolin-3-oner | |
| PT91571A (pt) | Verfahren fuer die herstellung von phyto und zoosterole und deren derivate mit verbesserter wasseroeslichkeit | |
| SE8504228L (sv) | Tumordodande emne | |
| SE8002602L (sv) | Diagnostiskt forfarande | |
| ATE94888T1 (de) | Verwendung von epithioderivaten ungesaettigter kohlenstoffverbindungen als weichmacher sowie diese enthaltende dichtungsmassen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8332 | No legal effect for de |